ライフサイエンスコーパス: were eligible to participate

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 ,658 participated in a telephone screening interview, 3,179 were eligible to participate in the genetic study, and 1,919

2 ts General Hospital between November 1992 and December 1996 were eligible to participate.

3 Patients who completed week 36 were eligible to participate in a long-term extension study (

4 In total, 238 of 252 patients (94.4%) were eligible to participate.

5 who were alive at the end of the original trial, 1658 (88%) were eligible to participate in the follow-up trial.

6 Patients with evidence of acute decompensated HF and ACS were eligible to participate.

7 HIV-1-infected adults were eligible to participate if they were treatment-experienc

8 All English-speaking persons older than 18 years of age were eligible to participate.

9 ed through the Piemonte and Valle d'Aosta register for ALS, were eligible to participate in the study.

10 domly sampled from each center; 3326 patients consented and were eligible to participate.

11 r induction therapy were assigned to a final risk group and were eligible to participate in a randomised comparison of in

12 ndetectable levels of hepatitis C virus RNA at 4 weeks) and were eligible to participate.

13 o City and who reported engaging in any homosexual behavior were eligible to participate in this study.

14 A total of 303 children were eligible to participate.

15 heir third trimester of pregnancy with perinatal depression were eligible to participate.

16 received any systemic treatment for their advanced disease were eligible to participate.

17 Women who delivered at the study facilities were eligible to participate and were recruited upon discharg

18 Infants were eligible to participate if they were 6-11 months old, av

19 e 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in these studies.

20 f reproductive age in 270 wards of Sarlahi district, Nepal, were eligible to participate.

21 Patients were eligible to participate if they were aged 20-60 years an

22 Patients completing the controlled phase were eligible to participate in the OLE phase and receive ope

23 th care-associated infection before the onset of the policy were eligible to participate.

24 All children aged 6 to 11 years at selected schools were eligible to participate.

25 All fourth-year students were eligible to participate during their mandatory four-week

26 ry or glaucoma surgery or complex posterior segment surgery were eligible to participate.

27 had failed or had a contraindication to standard therapies were eligible to participate.

28 ignancies who had disease progression on standard therapies were eligible to participate.

29 taining chemotherapy regimen and had available tumor tissue were eligible to participate in this study.

30 ne or more survey participants whose HIV status was unknown were eligible to participate in the trial.

31 ntemporary criteria for LVAD implantation for permanent use were eligible to participate in the trial.

32 ematology/Oncology Clinics at the University of Chicago who were eligible to participate in a phase I trial in which they

33 There was an estimated total of 3330 children who were eligible to participate, and data were recorded from 289

34 Of 167 found to have head lice, 81 (aged 3-14 years) were eligible to participate in a randomised controlled trial

35 All married women of reproductive age (15-49 years) were eligible to participate.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。